ATE283267T1 - O2-arylate oder o2 glycosyiate 1-substituierte diazen-1-ium-1,2 diolate und o2-substituierte 1 (2-carboxylate) pyrolidin-1-yl diazen-1-ium-1,2- diolate - Google Patents

O2-arylate oder o2 glycosyiate 1-substituierte diazen-1-ium-1,2 diolate und o2-substituierte 1 (2-carboxylate) pyrolidin-1-yl diazen-1-ium-1,2- diolate

Info

Publication number
ATE283267T1
ATE283267T1 AT97944471T AT97944471T ATE283267T1 AT E283267 T1 ATE283267 T1 AT E283267T1 AT 97944471 T AT97944471 T AT 97944471T AT 97944471 T AT97944471 T AT 97944471T AT E283267 T1 ATE283267 T1 AT E283267T1
Authority
AT
Austria
Prior art keywords
diolate
ium
substituted
diazene
glycosyiate
Prior art date
Application number
AT97944471T
Other languages
German (de)
English (en)
Inventor
Joseph E Saavedra
Larry K Keefer
Aloka Srinivasan
Christian Freidrich Bogdan
William G Rice
Xinhua Ji
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE283267T1 publication Critical patent/ATE283267T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/08Azoxy compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28Nitrogen atoms
    • C07D295/30Nitrogen atoms non-acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT97944471T 1996-09-27 1997-09-26 O2-arylate oder o2 glycosyiate 1-substituierte diazen-1-ium-1,2 diolate und o2-substituierte 1 (2-carboxylate) pyrolidin-1-yl diazen-1-ium-1,2- diolate ATE283267T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2681696P 1996-09-27 1996-09-27
US4591797P 1997-05-07 1997-05-07
US5169697P 1997-07-03 1997-07-03
PCT/US1997/017267 WO1998013358A1 (en) 1996-09-27 1997-09-26 O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates

Publications (1)

Publication Number Publication Date
ATE283267T1 true ATE283267T1 (de) 2004-12-15

Family

ID=27362853

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97944471T ATE283267T1 (de) 1996-09-27 1997-09-26 O2-arylate oder o2 glycosyiate 1-substituierte diazen-1-ium-1,2 diolate und o2-substituierte 1 (2-carboxylate) pyrolidin-1-yl diazen-1-ium-1,2- diolate

Country Status (7)

Country Link
US (3) US6610660B1 (US06610660-20030826-C00058.png)
EP (2) EP0929538B1 (US06610660-20030826-C00058.png)
AT (1) ATE283267T1 (US06610660-20030826-C00058.png)
AU (1) AU733590B2 (US06610660-20030826-C00058.png)
CA (2) CA2266908C (US06610660-20030826-C00058.png)
DE (1) DE69731758T2 (US06610660-20030826-C00058.png)
WO (1) WO1998013358A1 (US06610660-20030826-C00058.png)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
JP2003531179A (ja) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法
US20020064802A1 (en) * 2000-04-28 2002-05-30 Eva Raschke Methods for binding an exogenous molecule to cellular chromatin
WO2001092215A2 (en) * 2000-06-02 2001-12-06 Us Health Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
WO2002041902A1 (en) * 2000-11-27 2002-05-30 The University Of Akron Treatment of disorders using polyethylenimine diazeniumdiolate
CA2480033C (en) * 2002-03-21 2011-05-10 The University Of Utah Research Foundation In vivo use of glutathionone s-transferase activated nitric oxide donors
EP1507526A2 (en) 2002-05-07 2005-02-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
EP1545798A4 (en) * 2002-08-02 2006-06-14 Us Gov Health & Human Serv NETWORKED NITROGEN OXIDE RELEASING POLYAMINE-COATED SUBSTRATES, THESE COMPOSITIONS AND MANUFACTURING PROCESSES DAF R
WO2005011575A2 (en) * 2003-07-25 2005-02-10 The University Of Akron Stabilization and ionic triggering of nitric oxide release
CA2554771A1 (en) * 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
CA2555591C (en) * 2004-02-09 2011-01-04 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
US7569559B2 (en) 2004-02-09 2009-08-04 Noxilizer, Inc. Nitric oxide-releasing molecules
WO2005105171A1 (en) * 2004-04-29 2005-11-10 Cube Medical A/S A balloon for use in angioplasty with an outer layer of nanofibers
US20050265958A1 (en) * 2004-05-14 2005-12-01 West Jennifer L Nitric oxide releasing compositions and associated methods
CA2581939C (en) 2004-09-27 2013-01-08 Joseph A. Hrabie Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof
EP3556401A1 (en) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8021679B2 (en) 2005-08-25 2011-09-20 Medtronic Vascular, Inc Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
WO2007053292A2 (en) * 2005-10-31 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
EP1968615A4 (en) * 2005-12-06 2010-08-04 Amulet Pharmaceuticals Inc POLYMERS RELEASING NITRIC OXIDE
AU2007244903B2 (en) * 2006-04-24 2012-02-02 The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
FR2916757B1 (fr) * 2007-05-30 2009-07-17 Servier Lab Nouveaux derives diazeniumdiolates,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
CA2717867C (en) 2008-03-07 2017-05-30 Paul J. Shami Activated nitric oxide donors and methods of making and using thereof
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8852640B2 (en) * 2008-07-03 2014-10-07 Ecole Polytechnique Federale De Lausanne (Epfl) Micelles for delivery of nitric oxide
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
EP2498778A1 (en) * 2009-11-13 2012-09-19 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
RU2012138955A (ru) 2010-02-12 2014-03-20 Мерк Шарп Энд Домэ Корп. Циклопентилпроизводные диазенийдиолата
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
US9187501B2 (en) 2012-08-28 2015-11-17 The University Of North Carolina At Chapel Hill Nitric oxide-releasing nanorods and their methods of use
CN106459668A (zh) * 2014-04-16 2017-02-22 Sika技术股份公司 基于含硅烷基团的有机聚合物的迅速固化的无迁移组合物
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
JP6661289B2 (ja) * 2015-07-08 2020-03-11 三星ディスプレイ株式會社Samsung Display Co.,Ltd. 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
WO2017075460A1 (en) * 2015-10-29 2017-05-04 Arizona Board Of Regents On Behalf Of Arizona State University Skin-like condoms having active ingredients to enhance a male erection and a female arousal
WO2018067838A1 (en) 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
CA3055474A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
JP2021515083A (ja) * 2018-03-06 2021-06-17 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill 生分解性の抗菌性足場としての一酸化窒素放出性シクロデキストリンおよびそれに関する方法
US11421044B2 (en) 2018-12-28 2022-08-23 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153094A (en) 1959-06-10 1964-10-13 Du Pont Nitrosamine manufacture
US4954526A (en) 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5208233A (en) 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5721365A (en) * 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
US5212204A (en) 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
WO1993007114A1 (en) 1991-09-24 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5389675A (en) 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents
US5525357A (en) 1992-08-24 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5405919A (en) 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5691423A (en) 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
US5632981A (en) 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5700830A (en) * 1994-11-22 1997-12-23 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs

Also Published As

Publication number Publication date
US6610660B1 (en) 2003-08-26
EP0929538B1 (en) 2004-11-24
US6911433B2 (en) 2005-06-28
US20030147845A1 (en) 2003-08-07
US20050214249A1 (en) 2005-09-29
DE69731758T2 (de) 2005-12-15
CA2705474A1 (en) 1998-04-02
CA2266908C (en) 2010-07-20
DE69731758D1 (de) 2004-12-30
CA2705474C (en) 2013-07-16
WO1998013358A1 (en) 1998-04-02
AU733590B2 (en) 2001-05-17
EP2292630B1 (en) 2015-11-25
EP2292630A1 (en) 2011-03-09
AU4595797A (en) 1998-04-17
CA2266908A1 (en) 1998-04-02
EP0929538A1 (en) 1999-07-21
US7081524B2 (en) 2006-07-25

Similar Documents

Publication Publication Date Title
ATE283267T1 (de) O2-arylate oder o2 glycosyiate 1-substituierte diazen-1-ium-1,2 diolate und o2-substituierte 1 (2-carboxylate) pyrolidin-1-yl diazen-1-ium-1,2- diolate
EP1082960A3 (en) Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm
ID24387A (id) Oksidasi senyawa organik yang mendampingi paling sedikit 1 ikatan rangkap c-c
IS5258A (is) Pýrazín afleiður og notkun þeirra sem bólgueyðandi miðlar
BR9913097A (pt) Agente antiviral, e, derivado heterocìclico de carboxamida contendo nitrogênio
EA200000836A1 (ru) Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
IS2029B (is) Meðferðarlegar samsetningar sem innihalda amlódipín og atórvastatín
NO20022238L (no) Polycykloalkyl-puriner som adenosinreseptor-antagonister
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
MXPA05004779A (es) Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis.
ATE555789T1 (de) Pyridazinderivate und deren verwendung als therapeutische mittel
ATE511882T1 (de) Defibrillator mit detektion kardiopulmonarer wiederbelebung
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
WO2002002520A3 (en) Compounds to treat alzheimer's disease
ES2127965T3 (es) Derivados de acidos benzofuranil- y benzotiofenil-alcanocarboxilicos heterociclilcarbonil sustituidos.
WO2001096353A3 (en) 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES
NO324218B1 (no) Sulfonyl-pyrrolidin-derivater, medikamenter omfattende slike forbindelser, anvendelse av slike forbindelser for fremstilling av medikamenter for behandling og forebygging av sykdommer samt fremgangsmate for fremstilling av slike forbindelser
DK0672659T3 (da) Antitrombotiske midler
DK217588D0 (da) 17beta-(cyclopropylamino)-androst-5-en-3beta-olderivater, deres fremstilling og anvendelse som laegemidler
ATE353328T1 (de) Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung
ATE258797T1 (de) Verwendung von amifostin
CA2251132A1 (en) Use of phosphinyloxyalkyl and phosphonamidoalkyl derivatives of cyclopentane(ene) as therapeutic agents
KR970703763A (ko) 간 재생용 치료제(therapeutic agent for liver regeneration)
SE9900834D0 (sv) Novel combination
EE04040B1 (et) Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties